Chemomab Therapeutics (CMMB) Price to Earnings (2021 - 2026)

Chemomab Therapeutics (CMMB) has reported Price to Earnings for 6 consecutive years, with 5.38 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Earnings fell 49.39% year-over-year to 5.38; the trailing twelve-month figure through Jun 2026 stood at 1.54 (down 16.6% YoY), and the FY2025 full-year result was 1.32, down 46.1% from the prior year.
• Price to Earnings retreated to 5.38 in Q2 2026 per CMMB's latest filing, from 6.37 in the prior quarter.
• Across five years, Price to Earnings topped out at 11.52 in Q4 2024 and bottomed at 10.73 in Q1 2022.
• Historically, Price to Earnings has averaged 4.2 across 5 years, with a median of 4.9 in 2024.
• The sharpest annual moves came in 2023 and 2024: Price to Earnings sank 66.69% in 2023, then soared 556.82% in 2024.
• Over 5 years, Price to Earnings stood at 4.51 in 2022, then plunged by 61.12% to 1.75 in 2023, then jumped by 556.82% to 11.52 in 2024, then sank by 45.0% to 6.34 in 2025, then decreased by 15.06% to 5.38 in 2026.
• According to Business Quant data, Price to Earnings over the past three periods registered 5.38, 6.37, and 6.34 for Q2 2026, Q1 2026, and Q4 2025 respectively.